Literature DB >> 20132659

Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes.

Ramzi Jeddi1, Mériem Achour, Ramzi Ben Amor, Lamia Aissaoui, Walid Bouterâa, Karima Kacem, Raihane Ben Lakhal, Héla Ben Abid, Zaher BelHadjAli, Amel Turki, Balkis Meddeb.   

Abstract

Severe sepsis defined as infection-induced organ dysfunction or hypoperfusion abnormalities predispose to septic shock and increased mortality in neutropenic setting. We aimed at determining predictors of severe sepsis in neutropenic patients. Between 1 October and 31 December 2007, 41 patients (21 with acute myeloid leukemia, 19 with acute lymphoid leukemia and one with autologous stem cell transplantation for a mantle cell lymphoma) with chemotherapy-induced neutropenia (<0.5 x 10(9)/l) lasting for more than 7 days were included in this study. The median age was 28 years (range: 3-58 years). All patients were on oral antibacterial (colistin and gentamicin) and anti-fungal (amphotericin B) prophylaxis. The first neutropenic febrile episode was treated with piperacillin/tazobactam and colistin IV; if the patient remains febrile at 48 h from the start of this first line of treatment, amphotericin B i.v. is added. Imipenem was introduced in the case of non-response and finally glycopeptides were introduced according to the IDSA criteria. Severe sepsis and septic shock are defined according to the criteria of the consensus conference of the ACCP/SCCM excluding the leukocyte count since all the patients were neutropenic. Ninety-four febrile episodes were observed: 27 microbiologically documented (28.7%), six clinically documented (6.3%) and 61 fever of unknown origin (65%). Microbiologically documented infections were: 13 Gram-negative organisms, 11 Gram-positive organisms and three combined (Gram+ and -). Clinically documented infections were pneumonia (two), neutropenic enterocolitis (one), sinuses infection (one) and cutaneous infection (two). Severe sepsis accounted for 22 febrile episodes. Factors associated with the occurrence of severe sepsis were: hypophosphatemia (<0.8 mmol/l; p=0.05, OR=3.9, 95% CI: 1.3-45.7), hypoproteinemia (<62 g/l; p=0.006, OR=4.1, 95% CI: 1.4-11.4) and non-adapted antibiotherapy at the onset of severe sepsis (p=0.019, OR=2.7, 95% CI: 1.02-7.39). However, heart rate/systolic blood pressure ratio <1.1 (p<0.001, OR=0.1, 95% CI: 0.03-0.31) and Creactive protein <80 mg (p=0.001, OR=0.14, 95% CI: 0.04-0.54) were not predictive.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132659     DOI: 10.1179/102453310X12583347009577

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  12 in total

1.  Sepsis in the severely immunocompromised patient.

Authors:  Andre C Kalil; Steven M Opal
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

2.  Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.

Authors:  Mariana Chumbita; Pedro Puerta-Alcalde; Carlota Gudiol; Nicole Garcia-Pouton; Júlia Laporte-Amargós; Andrea Ladino; Adaia Albasanz-Puig; Cristina Helguera; Alba Bergas; Ignacio Grafia; Enric Sastre; María Suárez-Lledó; Xavier Durà; Carlota Jordán; Francesc Marco; Maria Condom; Pedro Castro; Jose A Martínez; Josep Mensa; Alex Soriano; Jordi Carratalà; Carolina Garcia-Vidal
Journal:  Antimicrob Agents Chemother       Date:  2021-11-29       Impact factor: 5.938

Review 3.  Bloodstream infections in neutropenic cancer patients: A practical update.

Authors:  Giulia Gustinetti; Malgorzata Mikulska
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

Review 4.  The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy.

Authors:  Judith A E M Zecha; Judith E Raber-Durlacher; Alexa M G A Laheij; Anneke M Westermann; Joel B Epstein; Jan de Lange; Ludi E Smeele
Journal:  Support Care Cancer       Date:  2019-06-20       Impact factor: 3.603

5.  Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients.

Authors:  Yeter Düzenli Kar; Zeynep Canan Özdemir; Özcan Bör
Journal:  Turk Pediatri Ars       Date:  2017-12-01

Review 6.  Neutropenic Enterocolitis and Sepsis: Towards the Definition of a Pathologic Profile.

Authors:  Giuseppe Bertozzi; Aniello Maiese; Giovanna Passaro; Alberto Tosoni; Antonio Mirijello; Stefania De Simone; Benedetta Baldari; Luigi Cipolloni; Raffaele La Russa
Journal:  Medicina (Kaunas)       Date:  2021-06-20       Impact factor: 2.430

Review 7.  Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).

Authors:  Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann
Journal:  Ann Hematol       Date:  2014-04-29       Impact factor: 3.673

8.  Independent factors for prediction of poor outcomes in patients with febrile neutropenia.

Authors:  Müge Günalp; Merve Koyunoğlu; Serdar Gürler; Ayça Koca; Ilker Yeşilkaya; Emre Öner; Meltem Akkaş; Nalan Metin Aksu; Arda Demirkan; Onur Polat; Atilla Halil Elhan
Journal:  Med Sci Monit       Date:  2014-10-05

9.  Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.

Authors:  Marie Shimanuki; Yorihisa Imanishi; Yoichiro Sato; Nana Nakahara; Daisuke Totsuka; Emiri Sato; Sena Iguchi; Yasuo Sato; Keiko Soma; Yasutomo Araki; Seiji Shigetomi; Satoko Yoshida; Kosuke Uno; Yusuke Ogawa; Takehiro Tominaga; Yuichi Ikari; Junko Nagayama; Ayako Endo; Koshiro Miura; Takuya Tomioka; Hiroyuki Ozawa; Kaoru Ogawa
Journal:  Oncotarget       Date:  2018-04-10

Review 10.  Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy.

Authors:  Federica Cennamo; Riccardo Masetti; Prisca Largo; Alberto Argentiero; Andrea Pession; Susanna Esposito
Journal:  Children (Basel)       Date:  2021-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.